About Amedisys (NASDAQ:AMED)
Amedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness. The Personal care segment provides patients with assistance with the essential activities of daily living.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Home Healthcare Services
- Sub-Industry: Health Care Services
- Symbol: NASDAQ:AMED
- CUSIP: 02343610
- Web: www.amedisys.com
- Market Cap: $1.70224 billion
- Outstanding Shares: 33,862,000
- 50 Day Moving Avg: $51.65
- 200 Day Moving Avg: $55.05
- 52 Week Range: $34.58 - $65.91
Sales & Book Value:
- Trailing P/E Ratio: 42.97
- Foreward P/E Ratio: 20.69
- P/E Growth: 1.18
- Annual Revenue: $1.45 billion
- Price / Sales: 1.17
- Book Value: $14.54 per share
- Price / Book: 3.46
- EBITDA: $105.65 million
- Net Margins: 2.70%
- Return on Equity: 13.71%
- Return on Assets: 8.56%
- Debt-to-Equity Ratio: 0.17%
- Current Ratio: 1.21%
- Quick Ratio: 1.21%
- Average Volume: 408,949 shs.
- Beta: 0.87
- Short Ratio: 4.52
Frequently Asked Questions for Amedisys (NASDAQ:AMED)
What is Amedisys' stock symbol?
Amedisys trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys' earnings last quarter?
Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analyst estimates of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys's revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $0.42 earnings per share. View Amedisys' Earnings History.
When will Amedisys make its next earnings announcement?
Where is Amedisys' stock going? Where will Amedisys' stock price be in 2017?
10 brokerages have issued 1-year target prices for Amedisys' shares. Their predictions range from $50.00 to $60.00. On average, they expect Amedisys' stock price to reach $56.20 in the next twelve months. View Analyst Ratings for Amedisys.
What are analysts saying about Amedisys stock?
Here are some recent quotes from research analysts about Amedisys stock:
- 1. Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
- 2. Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)
Who are some of Amedisys' key competitors?
Some companies that are related to Amedisys include Hutchison China MediTech Limited (HCM), Chemed Corp. (CHE), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Evotec AG (EVTCY), Agios Pharmaceuticals (AGIO), Penumbra (PEN), Advanced Accelerator Applications S.A. (AAAP), Mallinckrodt PLC (MNK), AveXis (AVXS), Neogen Corporation (NEOG), INC Research Holdings (INCR), Ligand Pharmaceuticals Incorporated (LGND), HealthEquity (HQY), Portola Pharmaceuticals (PTLA), NuVasive (NUVA), Wright Medical Group N.V. (WMGI) and GW Pharmaceuticals PLC (GWPH).
Who are Amedisys' key executives?
Amedisys' management team includes the folowing people:
- Paul B. Kusserow, President, Chief Executive Officer, Director
- Gary D. Willis, Chief Financial Officer
- Christopher T. Gerard, Chief Operating Officer
- Lawrence R. Pernosky, Chief Human Resource Officer
- Scott G. Ginn, Chief Accounting Officer
- Michael Paul North, Chief Information Officer
- David B. Pearce, Chief Compliance Officer
- David L. Kemmerly, General Counsel
- Stephen E. Seim, Chief Strategy Officer
- Susan Sender, Chief Clinical Operations Officer
Who owns Amedisys stock?
Amedisys' stock is owned by a number of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.06%) and Quantitative Systematic Strategies LLC (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, Jake L Netterville, Lawrence R Pernosky, North Tide Capital, Llc and Scott G Ginn. View Institutional Ownership Trends for Amedisys.
Who bought Amedisys stock? Who is buying Amedisys stock?
Amedisys' stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Quantitative Systematic Strategies LLC. View Insider Buying and Selling for Amedisys.
How do I buy Amedisys stock?
Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amedisys' stock price today?
MarketBeat Community Rating for Amedisys (NASDAQ AMED)MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Amedisys stock can currently be purchased for approximately $50.27.
Consensus Ratings for Amedisys (NASDAQ:AMED) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||6 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.40)|
|Consensus Price Target: ||$56.20 (11.80% upside)|Consensus Price Target History for Amedisys (NASDAQ:AMED)
Analysts' Ratings History for Amedisys (NASDAQ:AMED)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/23/2017||Royal Bank Of Canada||Reiterated Rating||Hold||N/A|
|10/12/2017||Jefferies Group LLC||Reiterated Rating||Buy||$60.00||N/A|
|10/9/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$60.00||N/A|
|10/4/2017||Robert W. Baird||Reiterated Rating||Hold||$50.00||Low|
|9/15/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Buy||$60.00||Low|
|8/21/2017||Bank of America Corporation||Initiated Coverage||Neutral -> Neutral||$55.00||Low|
|7/26/2017||Mizuho||Downgrade||Buy -> Neutral||$50.00||High|
|5/4/2017||Stephens||Boost Price Target||Equal Weight||$50.00 -> $54.00||Low|
|5/3/2017||Benchmark Co.||Reiterated Rating||Hold -> Hold||$50.00 -> $57.00||High|
|1/17/2017||Craig Hallum||Set Price Target||Buy||$60.00||N/A|
|9/11/2016||Wells Fargo & Company||Reiterated Rating||Buy||N/A|
|1/11/2016||Raymond James Financial, Inc.||Upgrade||Underperform -> Market Perform||N/A|
|11/6/2015||Piper Jaffray Companies||Reiterated Rating||Neutral||$42.00 -> $45.00||N/A|
Earnings History for Amedisys (NASDAQ:AMED)Earnings History by Quarter for Amedisys (NASDAQ AMED)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/26/2017||Q2 2017||$0.50||$0.62||$380.80 million||$378.80 million||View||N/A|
|5/2/2017||Q1 2017||$0.41||$0.47||$370.03 million||$370.46 million||View||Listen|
|2/28/2017||Q4 2016||$0.39||$0.44||$368.14 million||$366.30 million||View||N/A|
|11/3/2016||Q3||$0.36||$0.36||$361.08 million||$361.60 million||View||Listen|
|8/2/2016||Q2||$0.42||$0.42||$353.07 million||$360.00 million||View||Listen|
|5/3/2016||Q1||$0.33||$0.33||$337.07 million||$348.80 million||View||Listen|
|3/8/2016||Q415||$0.35||$0.40||$322.67 million||$338.37 million||View||Listen|
|11/5/2015||Q315||$0.34||$0.34||$312.22 million||$326.50 million||View||Listen|
|7/29/2015||Q215||$0.33||$0.43||$307.11 million||$314.20 million||View||Listen|
|4/29/2015||Q115||$0.20||$0.30||$300.17 million||$301.60 million||View||Listen|
|3/4/2015||Q414||$0.27||$0.27||$301.62 million||$300.50 million||View||Listen|
|10/29/2014||Q314||$0.17||$0.28||$299.26 million||$300.30 million||View||Listen|
|7/30/2014||Q214||$0.17||$0.25||$298.90 million||$305.00 million||View||Listen|
|5/8/2014||Q114||($0.06)||($0.07)||$301.89 million||$298.74 million||View||Listen|
|3/12/2014||Q413||($0.01)||($0.05)||$295.02 million||$303.50 million||View||Listen|
|11/12/2013||Q313||$0.13||$0.06||$314.30 million||$301.64 million||View||Listen|
|7/31/2013||Q2 2013||$0.10||$0.06||$328.02 million||$313.10 million||View||Listen|
|4/30/2013||Q1 2013||$0.18||$0.13||$361.41 million||$339.20 million||View||Listen|
|3/12/2013||Q4 2012||$0.22||$0.24||$373.31 million||$632.90 million||View||Listen|
|11/6/2012||Q312||$0.27||$0.33||$379.97 million||$375.62 million||View||N/A|
Earnings Estimates for Amedisys (NASDAQ:AMED)
2017 EPS Consensus Estimate: $2.03
2018 EPS Consensus Estimate: $2.52
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Amedisys (NASDAQ:AMED)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Amedisys (NASDAQ:AMED)
Insider Ownership Percentage: 2.00%Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Institutional Ownership Percentage: 96.55%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/8/2017||David B Pearce||Insider||Sell||1,000||$50.00||$50,000.00|| |
|8/3/2017||Bruce D Perkins||Director||Buy||2,000||$46.60||$93,200.00|| |
|5/25/2017||Bruce D Perkins||Director||Buy||500||$59.69||$29,845.00|| |
|5/12/2017||Jake L Netterville||Director||Sell||10,000||$60.00||$600,000.00|| |
|5/10/2017||Lawrence R Pernosky||Insider||Sell||11,500||$58.97||$678,155.00|| |
|5/9/2017||Lawrence R Pernosky||Insider||Sell||11,500||$58.78||$675,970.00|| |
|5/8/2017||Scott G Ginn||Insider||Sell||23,828||$58.62||$1,396,797.36|| |
|5/13/2016||Bruce D Perkins||Director||Buy||1,000||$50.21||$50,210.00|| |
|5/11/2016||Scott G Ginn||Insider||Sell||6,000||$51.62||$309,720.00|| |
|11/2/2015||North Tide Capital, Llc||Major Shareholder||Sell||277,720||$39.79||$11,050,478.80|| |
|10/28/2015||North Tide Capital, Llc||Major Shareholder||Sell||191,400||$39.86||$7,629,204.00|| |
|10/26/2015||North Tide Capital, Llc||Major Shareholder||Sell||56,400||$39.32||$2,217,648.00|| |
|8/18/2015||Donald A Washburn||Director||Sell||20,000||$45.51||$910,200.00|| |
|3/13/2015||Jeffrey D Jeter||Insider||Sell||11,264||$27.02||$304,353.28|| |
|3/13/2015||Peter Ricchiuti||Director||Sell||2,003||$27.25||$54,581.75|| |
|8/5/2014||Jeffrey D Jeter||Insider||Sell||2,500||$21.80||$54,500.00|| |
|5/8/2014||North Tide Capital, Llc||major shareholder||Buy||500,000||$13.90||$6,950,000.00|| |
|5/1/2014||North Tide Capital, Llc||major shareholder||Buy||150,000||$13.54||$2,031,000.00|| |
|11/21/2013||Kkr Asset Management Llc||major shareholder||Buy||425,515||$14.48||$6,161,457.20|| |
|11/15/2013||David Bucey||General Counsel||Sell||8,290||$13.95||$115,645.50|| |
|11/14/2013||Kkr Asset Management Llc||major shareholder||Buy||946,500||$13.89||$13,146,885.00|| |
|10/30/2013||Kkr Asset Management Llc||Major Shareholder||Buy||29,615||$15.94||$472,063.10|| |
|10/22/2013||Kkr Asset Management Llc||Major Shareholder||Buy||186,013||$17.55||$3,264,528.15|| |
|10/18/2013||Kkr Asset Management Llc||Major Shareholder||Buy||12,652||$17.95||$227,103.40|| |
|7/3/2013||Linda J Hall||Director||Sell||1,721||$10.65||$18,328.65|| |
Headline Trends for Amedisys (NASDAQ:AMED)
Latest Headlines for Amedisys (NASDAQ:AMED)
Loading headlines, please wait.
Amedisys (AMED) Chart for Monday, October, 23, 2017